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ABSTRACT
Ebola virus disease (EVD) is one of the most lethal transmissible infections characterized by a high fatality rate, and a
treatment has not been developed yet. Recently, it has been shown that cationic amphiphiles, among them the
antiarrhythmic drug amiodarone, inhibit filovirus infection. In the present work, we investigated how amiodarone
interferes with Ebola virus infection. Wild-type Sudan ebolavirus and recombinant vesicular stomatitis virus, pseudotyped
with the Zaire ebolavirus glycoprotein, were used to gain further insight into the ability of amiodarone to affect Ebola virus
infection. We show that amiodarone decreases Ebola virus infection at concentrations close to those found in the sera of
patients treated for arrhythmias. The drug acts by interfering with the fusion of the viral envelope with the endosomal
membrane. We also show that MDEA, the main amiodarone metabolite, contributes to the antiviral activity. Finally, studies
with amiodarone analogues indicate that the antiviral activity is correlated with drug ability to accumulate into and
interfere with the endocytic pathway. Considering that it is well tolerated, especially in the acute setting, amiodarone
appears to deserve consideration for clinical use in EVD.
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INTRODUCTION
Ebola virus disease (EVD) is a disease of human and non-
human primates, caused by five genetically distinct mem-
bers of the Ebolavirus genus, Filoviridae family. So far Zaire,
Sudan and Bundibugyo viruses have been responsible
for most of the human EVD outbreaks (Feldmann and
Geisbert 2011). Ebola virus (EBOV) infects a broad range of
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cell types (Feldmann and Geisbert 2011). Binding and entry into
target cells are mediated by the viral glycoprotein GP, a class I
fusion protein composed of a receptor binding subunit (GP1)
and a fusion subunit (GP2) (Lee et al. 2008; Lee and Saphire
2009. After initial internalization via macropinocytosis, virus
particle trafficking into the endolysosomal pathway ends up
into late endosomes, where the low-pH-dependent cysteine
proteases cathepsins B and L allow processing of the GP1 into
a 19 kDa fusogenic form (Chandran et al. 2005; Schornberg
et al. 2006; Dube et al. 2009; Hood et al. 2010; Miller et al. 2012).
Subsequently, the interaction between the processed GP1 and
the late endosomal/lysosomal protein Neimann–Pick C1 (NPC-1)
leads to GP2-dependent fusion of the viral envelope with the
limiting membrane of the endosomes (Carette et al. 2011; Cote
et al. 2011; Miller et al. 2012). NPC-1 protein is necessary for virus
infectivity, as cells from patients with Neimann–Pick disease,
due to lack or malfunction of the NPC-1 protein, are resistant to
EBOV infection (Carette et al. 2011). In addition to the NPC-1, it
has been recently demonstrated that EBOV entry into the target
cells requires also the presence of the endosomal/lysosomal
calcium channels called two-pore channels (Sakurai et al.
2015).
Multiple cationic amphiphiles have been reported to in-
hibit EBOV infection (Carette et al. 2011; Johansen et al. 2013;
Shoemaker et al. 2013). In particular, it has been shown that
the antiarrhythmic drugs amiodarone and dronedarone, multi-
ion channel inhibitors, inhibit filovirus infection acting at an
early step of viral life cycle (Gehring et al. 2014). Interest-
ingly, amiodarone and dronedarone induce an NPC-like phe-
notype in several cell types (Morissette et al. 2009; Piccoli et al.
2011).
Here we found that (i) amiodarone inhibits the fusion of
the Zaire ebolavirus glycoprotein (ZEBOV GP) with the endoso-
mal membrane; (ii) amiodarone and its main metabolite mon-
odesethyl amiodarone (MDEA) potently inhibit Sudan ebolavirus
(SUDV) entry and progeny release from infected cells; (iii) the an-
tiviral activity correlates with amiodarone ability of inducing an
NPC-like phenotype.
Since all these effects were observed at concentrations close
to those found in the sera of patients treated for arrhythmias,
it appears that amiodarone could be an attractive candidate for
the treatment of EVD.
MATERIALS AND METHODS
Cells, plasmids and compounds
Human embryonic kidney (HEK293T) cells and African green
monkey kidney Vero cells were grown at 37◦C with 5% CO2 in
Dulbecco’s modified Eagle’s medium (Life Technologies) sup-
plemented with 10% heat-inactivated foetal bovine serum (Life
Technologies).
The plasmid expressing the ZEBOV GP, pVR-1012-ZEBOV-
GP, was kindly provided by Gary Nabel (Vaccine Research Cen-
ter, NIH, Bethesda, USA). The plasmid expressing the vesicular
stomatitis virus (VSV) glycoprotein (pVSV-G) was previously de-
scribed (Salata et al. 2009).
Amiodarone was purchased from Sigma-Aldrich.
Dronedarone was extracted from Multaq pills (Sanofi-
Aventis) as previously described (Piccoli et al. 2011). Syn-
thesis and characteristics of amiodarone analogues (Fig. 1)
have been previously reported (Quaglino et al. 2004; Ha et al.
2005).
Infection assays with the GP-pseudotyped virus
and SUDV
The recombinant VSV containing the gene encoding the green
fluorescent protein in place of the VSV-G gene (VSVG-GFP) was
provided by Michael Whitt, University of Tennessee, USA. ZE-
BOV GP pseudotyped VSVG-GFP (GP-pseudotyped virus) was
generated as previously described (Whitt 2010). Briefly, HEK293T
cells were transfected by Lipofectamine 2000 (Life Technologies)
with 16 μg of pVR-1012-ZEBOV-GP plasmid and infectedwith the
recombinant VSVG-GFP virus at the multiplicity of infection
(MOI) of 4 fluorescent focus-forming units (FFU)/cell. After 48 h,
virus was harvested and stored at −80◦C. Viral titer was eval-
uated by cytofluorimetric analysis (FACScalibur, Becton Dickin-
son) of Vero cells infected with limiting dilutions of viral stock,
and data were analysed by CellQuest software.
In the antiviral activity assays, Vero cells were exposed to the
appropriate compound for the time indicated. Next, cells were
infected with recombinant viruses (MOI of 0.1 FFU/cell) and 24 h
later GFP-positive cells were evaluated.
Infection with the SUDV was performed by adding the virus
(MOI of 0.05 FFU/cell) to Vero cells. One hour later, unbound
viruswas removed and freshmediumwith the appropriate com-
pound was added. After 24 h, cells were fixed with ice-cold
methanol/acetone at −20◦C for 30 min. Cells were processed
for immunofluorescence using an antibody targeting the viral
nucleoprotein, as previously described (Weidmann et al. 2011).
Viral progeny release was evaluated on supernatants collected
48 h post-infection by immunostaining of infected Vero cells.
All the experiments with SUDV were performed in the biosafety
level 4 laboratory at the Public Health Agency of Sweden, Solna,
Sweden.
Fusion assay
Vero cells grown on 13-mm coverslips were kept in control
medium or pretreated for 16 h with either 10 μM amiodarone or
20 μM U18666A. Subsequently, cells were incubated for 3 h with
GP-pseudotyped virus (MOI of 20 FFU/cell). Next, cells were fixed
for 20 min with 2% paraformaldehyde (Sigma-Aldrich), and per-
meabilized for 30 min with 0.1% Triton X-100 (Sigma Aldrich).
VSV matrix (VSV-M) protein was detected by incubations for
30min at 37◦Cwith 23H12 antibody (Kerafast Inc.), and thenwith
Alexa 568-conjugated antibody (Life Technologies). Cells were
counterstained with DRAQ5TM (Cell Signaling Technology) to vi-
sualize the nuclei. Images were acquired using a Nikon A1 con-
focal microscope (Nikon Instruments).
Cathepsin B and L activity assay
Cathepsin B substrate (Z-Arg-Arg-MCA) and Cathepsin L sub-
strate (Z-Phe-Arg-MCA), both fromSigma-Aldrich,were stored at
−80◦C as 10mM inDMSO stocks, and diluted to 100μMwith 0.1%
Brij (Sigma-Aldrich) just before use. 10 mM in DMSO stocks of
cathepsin B inhibitor CA-074Me (Calbiochem) was prepared and
stored at −80◦C. The concentration was brought to 25 μM with
reaction buffer just before use. To measure the effects of amio-
darone on cathepsin activity, Vero cells were grown to semi-
confluence in six well plates. Three wells were incubated for
12 h with 10 μM amiodarone, while three wells served as con-
trols. At the end of the incubation, cells were rinsed with cold
PBS, pooled by scraping in two Eppendorf tubes, washed two
more times with cold PBS and lysed in 200 μl of 100 mM sodium
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Figure 1. Amiodarone and analogues. (a) Amiodarone structural determinants: benzofuran moiety with butyl lateral group (I), diiodobenzoyl moiety (II) and
diethylamino-β-ethoxy moiety with tertiary nitrogen atom (III). (b) Analogues listed in order of decreasing hydrophobicity; + or − indicate the ability of inducing
an NPC-like phenotype and of inhibiting GP-mediated viral entry at the concentrations used in this work (0.3 μM dronedarone, 0.3 μM DDEA, 0.3 μM B2-O-EtOH, 2 μM
MDEA, all other 10 μM).
acetate, 1 mM EDTA, 0.5% Triton, pH 5.0 for 10min in ice. Lysates
were then centrifuged at 12 000 × g for 6 min and the super-
natants were stored at −80◦C. Cathepsin assay (Ebert et al. 2002)
was performed by using 0.5–5 μg of protein lysates and 50 μM
of substrate in a total volume of 200 μl by combining (a) 80 μl
of reaction buffer (100 mM sodium acetate, 1 mM EDTA, 4 mM
dithiothreitol, pH 5.0) and 100 μl of Z-Arg-Arg-MCA solution
(cathepsin B assay); (b) 80 μl of CA-074Me in reaction buffer
(final concentration 10 μM) and 100 μl of Z-Phe-Arg-MCA
(cathepsin L assay); (c) 80 μl of reaction buffer and 100 μl of
Z-Phe-Arg-MCA (cathepsin B+L assay). The reaction, allowed to
proceed for 1 h at 37◦C in the dark, was stopped by the addition
of 200 μl of cold reaction buffer. Fluorescence was measured by
using a fluorometer with an excitation of 390 nm and an emis-
sion of 460 nm.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Differ-
ences were analysed by a Student’s ‘t’ test. The level of accepted
significance was P < 0.05.
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RESULTS
Amiodarone and its metabolite MDEA inhibit EBOV
infection in vitro
It has been recently reported that amiodarone inhibits filovirus
replication in vitro, while the mechanism of inhibition remains
unclear (Gehring et al. 2014). In patients with arrhythmia chron-
ically treated with 200–600 mg day−1 amiodarone, drug plasma
concentration ranges from 1.7 ± 0.6 to 5.1 ± 0.2 μM, while af-
ter intravenous administration, plasma levels can increased up
to 11 μM (Ha et al. 2005; Breitenstein et al. 2008). We have previ-
ously reported that 16 h of incubation with 10 μM amiodarone
induces a full-fledged NPC-like phenotype (Piccoli et al. 2011). In
order to confirm the anti-ebolavirus activity of amiodarone and
to analyse whether the NPC-like phenotype plays a role at this
level, Vero cells were incubated for 16 h with 2, 5 or 10 μM amio-
darone which previously displayed no appreciable cytotoxicity
(Piccoli et al. 2011). Cells were then infected with recombinant
VSV encoding for the green fluorescent protein (GFP) in place
of the glycoprotein G (VSVG-GFP), pseudotyped with either
the envelope glycoprotein G of the VSV (VSV-recombinant virus)
or the ZEBOV-envelope glycoprotein (GP-pseudotyped virus). A
MOI of 0.1 FFU/cell was employed to achieve a percentage of
infected cells which allows, with all the recombinant viruses
tested, the evaluation of the antiviral effect without saturat-
ing the system. Two hours post-infection, cells were rinsed and
incubated for additional 24 h in the presence of the appropri-
ate drug concentration before evaluating GFP-positive cells by
cytofluorimetry. The 2 h time frame was selected in order to
ensure the adhesion to the target cells of all the used recom-
binant viruses, in the adopted experimental settings. Our re-
sults show that amiodarone inhibited GP-pseudotyped virus in a
dose-dependent manner with an estimated IC50 (half maximal
dose inhibitory concentration) of 5.6 μM (Fig. 2a). By contrast,
the drug did not display such an effect on VSV-recombinant
virus.
Next, to further dissect the mechanisms by which amio-
darone inhibit the infection, GP-pseudotyped virus (MOI of 0.1
FFU/cell) was incubated with Vero cells untreated (no drug) or
exposed to amiodarone for 16 h before infection (t −16), during
viral adhesion (t 2), before and after (t −16 + t 24) or only after
adhesion (t 24) (Fig. 2b). Cell fluorescence was then measured.
We found a significant reduction in GFP-positive cells both with
amiodarone pretreatment (t −16) and when amiodarone was
present during viral adhesion (t 2). Only a limited effect was ob-
served when amiodarone was added after viral adhesion (t 24).
These results suggest that amiodarone could interfere with in-
fection both by a direct effect during viral entry and through the
induction of an NPC-like phenotype.
The above findings were confirmed in an experimental set-
ting in which SUDV was used to infect Vero cells (MOI of 0.05
FFU/cell) either untreated (no drug) or treated with 10 μM amio-
darone 16 h before and 24 h after infection (t −16 + t 24), during
1 h of viral adhesion (t 1), during and 24 h after adhesion (t 1 +
t 24), or after adhesion, i.e. immediately (t 24) or 3 h post-viral ad-
hesion (t 21) (Fig. 3). Cells were then analysed by immunofluores-
cence. SUDV infection was significantly inhibited (95.9 ± 0.2%)
in the t −16 + t 24 condition (Fig. 3). Furthermore, 91.7 ± 2.9%
of inhibition was also achieved with the t 1 + t 24 condition,
while the treatment performed only during the adhesion (t 1)
caused an inhibition of 81.3 ± 8.9% (Fig. 3). However, when the
drugwas added after the adhesion step, the effect of amiodarone
was smaller, especially when the drug was added with 3 h delay
(t 21) (Fig. 3). Furthermore, the amiodarone effect was stronger
Figure 2. Amiodarone inhibits GP-mediated entry. (a) Vero cells treated for
16 hwith amiodaronewere infected for 2 hwith the VSVG-GFP virus (MOI of 0.1
FFU/cell) bearing its native glycoprotein (VSV-recombinant virus) or the EBOV GP
glycoprotein (GP-pseudotyped virus). After 24 h, GFP-positive cells were assayed
by cytofluorimetry. (b) Vero cells treated with 10 μM amiodarone, as indicated,
were infected for 2 h with GP-pseudotyped virus (MOI of 0.1 FFU/cell). After 24 h,
GFP-positive cellswere quantified by cytofluorimetry. No drug indicates no amio-
darone treatment, (t –16) indicates 16 h of treatment before infection, (t + 24)
stands for 24 h of treatment after infection, (t 2) indicates treatment during viral
adhesion. Data (mean ± SD, N = 3 experiments in duplicate) are percentages of
GFP-positive cells with respect to no drug, set as 100% (∗ = P < 0.05).
than the one observed in the presence of U18666A, a compound
known to block the fusion of the EBOV envelope with the endo-
somal membrane (Carette et al. 2011; Shoemaker et al. 2013)
MDEA, the main metabolite of amiodarone, reaches plasma
concentrations close to those of the parent drug and contributes
both to antiarrhythmic activity and toxicity (Quaglino et al. 2004;
Ha et al. 2005; Piccoli et al. 2011). To investigate whether MDEA
affects EBOV entry, Vero cells were incubated for 16 h with 2 or
10 μM amiodarone, 2 μM MDEA or with a combination of 2 μM
amiodarone and 2 μM MDEA (a common condition in patients
taking amiodarone chronically). Next, cells were infected with
GP-pseudotyped virus (MOI of 0.1 FFU/cell), and 24 h later the
infectivity was evaluated by cytofluorimetry. While amiodarone
inhibits GP-pseudotyped virus infection more efficiently than
MDEA, the combination of 2 μM amiodarone and 2 μM MDEA
had a stronger inhibitory effect than the one achieved by treat-
ment with each compound alone (Fig. 4a).
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Figure 3. Amiodarone interferes with early steps of SUDV infection. Vero cells,
treated with 10 μM amiodarone, were infected for 1 h with 0.05 FFU/cell of SUDV.
After 24 h, infected cells were identified by staining with an antibody anti-SUDV
Nucleoprotein (NP). No drug indicates no amiodarone treatment, (t –16) stands
for 16 h treatment before infection, (t 1) indicates treatment during infection,
(t 24) indicates a treatment of 24 h following infection and (t 21) indicates 21 h
treatment starting 3 h after infection. Data (mean ± SD, N = 2 experiments in
duplicate) are percentages of NP-positive cells with respect to no drug, set as
100% (∗ = P < 0.05).
To further evaluate the effect of the amiodarone/MDEA com-
bination on EBOV infection, we employed SUDV at the MOI of
0.05 FFU/cell. Twenty-four h later, viral entry was evaluated by
indirect immunofluorescence, while progeny release was tested
by viral titration at 48 h. U18666A and dronedarone were also
included. In particular, dronedarone was used at a concentra-
tion of 0.3 μM, which is found in patients chronically treated
by the oral route. Results showed that amiodarone and MDEA
in combination inhibited viral entry and progeny release and
that their effect was stronger than the one due to dronedarone
and U18666A (Fig. 4b and c). We conclude that amiodarone and
MDEA, at concentrations of clinical significance, inhibit EBOV
infection.
Amiodarone inhibits EBOV fusion with
the endosomal membrane
Since our data demonstrate that amiodarone has an effect on
the early phases of ebolavirus replication, we focused our atten-
tion on the key step of viral envelope/endosomal membrane fu-
sion. Vero cells, treated for 16 h with 10 μM amiodarone, were
incubated for 3 h with GP-pseudotyped virus or with the VSV-
recombinant virus as a control (MOI of 20 FFU/cell). Next, cells
were fixed and stained with an anti-VSV-M antibody (Carette
et al. 2011). As shown in Fig. 5, untreated cells displayed a diffuse
cytoplasmatic staining, with both GP-pseudotyped and VSV-
recombinant viruses, indicating that the fusion of the viral en-
velope with the endosomal membrane occurred, allowing the
release of VSV-M protein into the cytoplasm. By contrast, in the
presence of amiodarone or U18666A, while in cells infected with
VSV-recombinant virus a diffuse staining was observed, most of
the cells infected by GP-pseudotyped virus displayed a punctate
staining (Fig. 5). Similar results were also observed when cells
were treated with amiodarone during the 3 h of viral incubation
(data not shown).
Figure 4. Amiodarone and metabolite MDEA have additive antiviral activity.
(a) Amiodarone and MDEA inhibit GP-dependent entry. Vero cells treated for 16
h with amiodarone or MDEA were infected for 2 h with GP-pseudotyped virus
(MOI of 0.1 FFU/cell). Afterwards, cells were exposed to the same concentration
of compounds for additional 24 h and then were evaluated by cytofluorimetry.
Data (mean ± SD, N = 4 experiments conducted in duplicate) are percentages of
GFP-positive cells with respect to no drug, set as 100%. (b) Effect of amiodarone,
MDEA and dronedarone on SUDV entry. Vero cells treated for 16 h with amio-
darone, amiodarone+MDEA, dronedarone or U18666Awere infected with SUDV
for 1 h (MOI of 0.05 FFU/cell). Afterwards, cells were exposed to the same con-
centration of each compound for further 24 h, and viral entry was evaluated by
immunostaining of SUDV Nucleoprotein with a specific antibody. (c) Evaluation
of infectious viral particles release. Vero cells treated for 16 h with amiodarone,
amiodarone + MDEA, dronedarone or U18666A were infected with SUDV as re-
ported above. Then, cells were exposed for 48 h to the same concentration of
each compound. Next, viral particles released in the supernatants were titrated
by infecting Vero cells and by counting SUDV Nucleoprotein-positive cells by flu-
orescence microscopy. Data in (b) and (c) (mean ± SD, N = 2 experiments in du-
plicate) are percentages of no drug, set as 100% (∗ = P < 0.05).
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Figure 5. Amiodarone blocks fusion of GP-pseudotyped virus with the endosomal membranes. Vero cells treated for 16 h with 10 μM amiodarone or 20 μM U18666A
were infected for 3 h with GP-pseudotyped virus (upper panels) or VSV-recombinant virus (lower panels) (MOI of 20 FFU/cell). Three hours post-infection, the VSV-M
protein was stained with 23H12 specific antibody (red). Nuclei were stained with DRAQ5TM (blue). Scale bar of confocal images: 25 μm.
Figure 6. Amiodarone antiviral effect is rescued by in vitro proteolysis of GP. (a) Amiodarone does not affect the cell content of cathepsins B and L. Vero cells treated
for 12 h with 10 μM amiodarone were lysed and cathepsin activity was measured in the cell lysates. Data (mean ± SD) are presented as percentages of Cat B + Cat L
measured in the absence of drug (no drug). (b) In vitro proteolysis of GP rescues viral infectivity. Vero cells, treated for 16 h with 10 μM amiodarone, were incubated for
2 h with GP-pseudotyped virus (MOI of 0.1 FFU/cell) treated for 1 h with either reaction buffer alone (mock pre-activated) or 0.2 mg ml–1 thermolysin (pre-activated).
Cells were then incubated for 24 h in plain medium (no drug) or with 10 μM amiodarone, GFP-positive cells were estimated by cytofluorimetry. Data (mean ± SD, N =
3 experiments in duplicate) are percentages of GFP-positive cells with respect to cells exposed to mock pre-activated virus in the absence of amiodarone, set as 100%
(∗ = P < 0.05).
During viral entry, virion-associated GP is processed by
cathepsins B and L into the 19 kDa fusogenic form (Martinez et al.
2013). Although amiodarone did notmodify the total cell content
of cathepsins B and L (Fig. 6a), incubation of GP-pseudotyped
virus with thermolysin before infection, a treatment that allows
the in vitro processing of the GP1 into the 19 kDa form, clearly
rescued viral infectivity (Fig. 6b). Overall these data suggest that
amiodarone affects GP-driven fusion.
Role of different structural groups of amiodarone
on its antiviral activity
To clarify the structural basis of amiodarone ability to inter-
fere with EBOV infection, we analysed the effect of amiodarone
analogues (Fig. 1) on GP-pseudotyped virus infection. Analogues
have already been tested for their toxicity and ability of inducing
anNPC-like phenotype (Quaglino et al. 2004; Bigler et al. 2007; Pic-
coli et al. 2011). Vero cells were treated for 16 h with amiodarone
or its analogues (at concentrations of clinical relevance, when
applicable, or at the ones sufficient to induce an NPC-like phe-
notype without being toxic to cells) and then incubated for 2 h
with GP-pseudotyped virus (MOI of 0.1 FFU/cell). Infected cells
were maintained in medium containing the appropriate com-
pound for additional 24 h, and GFP-positive cells were evalu-
ated by cytofluorimetry. As shown in Fig. 7, the diethylamino-β-
ethoxy lateral group, which is a determinant for accumulation
into acidic organelles, is required for antiviral activity. Further-
more, it appears that, among the compounds bearing this group,
the antiviral activity correlates with the ability of inducing an
NPC-like phenotype (MeAmi > Amiodarone > PIPAM > MDEA)
(Piccoli et al. 2011). In addition, a bulky benzofuran hydrophobic
moiety is necessary for the antiviral activity, as D2, which has
the diethylamino-β-ethoxy group but lacks a hydrophobic moi-
ety, is inactive. Of note, the amiodarone metabolite didesethyl
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Figure 7. Structural determinants of amiodarone antiviral activity. Vero cells were treated for 16 h with different compounds. Amiodarone, MDEA and dronedarone
concentrations were close to maximum serum levels found in patients. The concentration of different analogues was the maximum achieved without cell toxicity.
After 16 h of preincubation with amiodarone and its analogues, cells were infected for 2 h with GP-pseudotyped virus (MOI of 0.1 FFU/cell), and then exposed to the
same concentration of each compound for additional 24 h. GFP-positive cells were then evaluated by cytofluorimetry. Data (mean ± SD,N= 4 experiments in duplicate)
are percentages of no drug set as 100% (∗ = P < 0.05).
amiodarone (DDEA), usually found in traces in serum, is devoid
of antiviral activity.
Overall, the antiviral activity of amiodarone seems to corre-
late with motifs which lead to an expanded lysosome pheno-
type (Logan et al. 2014), namely the presence of an amine group,
amphiphilicity, a bulky hydrophobic moiety and the ability to be
incorporated intomembranes (Mitterreiter et al. 2010). It also ap-
pears that subtle changes of the alkyl group of the diethylamino-
β-ethoxy chain (as in the MeAmi compound) might increase
amiodarone antiviral effect.
DISCUSSION
EVD is one of the most lethal transmissible infections. Although
in the past this disease appeared sporadically, the increase of
human incursions into endemic regions and the higher mobil-
ity have turned EBOV into a high-priority public threat. This is
sadly confirmed by the biggest epidemic outbreak ever, currently
occurring in the Western Africa (CDC 2014). The fast track ac-
cess to treatment options for EVD is a key priority for the World
Health Organization (WHO). With worst-ever outbreak of Ebola
raging in West Africa, WHO concluded that it is ethical to use
unproven drugs and vaccines to try to combat the disease. How-
ever, no medicines so far have been approved, for routine use in
EVD.
Currently, despite the fact that different anti-EBOV com-
pounds have been reported in the literature, their antiviral effi-
cacy has been evaluated only in vitro and in animalmodels (Basu
et al. 2011; Cote et al. 2011; Iversen et al. 2012; Johansen et al. 2013;
Madrid et al. 2013; Shoemaker et al. 2013; Elshabrawy et al. 2014;
Gehring et al. 2014; Oestereich et al. 2014; Picazo and Giordanetto
2014; Warren et al. 2014). Even though some of these compounds
have been already approved for treatment of human diseases
(Johansen et al. 2013; Shoemaker et al. 2013; Gehring et al. 2014),
no clinical trials to evaluate their safety and efficacy in EVD have
been completed so far. In this respect, the identification of com-
mercially available drugs, already approved for the use in hu-
mans, and active against EBOV, might accelerate the organiza-
tion of clinical trials and eventually clinical use.
Recently, Gehring et al. (2014) demonstrated that amiodarone
and dronedarone, drugs approved for the treatment of cardiac
arrhythmias, inhibit filovirus infection. The aim of the present
work was to further characterize the effect of amiodarone on
EBOV infection. Interestingly, we found that amiodarone inhibits
EBOV infection in a dose-dependent manner and at concen-
trations comparable to plasma levels found in intravenously
treated patients. The IC50 of amiodarone calculated by em-
ploying a recombinant GP-pseudotyped VSV on Vero cells was
5.6 μM. It has to be mentioned that a recent study (Gehring et al.
2014) reported an IC50 of amiodarone around 2.2 μM, with a GP-
pseudotyped lentivirus, and around 0.4 μMwith the ZEBOV. Tak-
ing into account the different viral/cellular systems employed,
overall these data indicate that amiodarone efficiently inhibits
EBOV infection. The antiviral potency varies with the timing of
cell exposure to the drug. Inhibition is maximum when amio-
darone pretreatment induces an NPC-like phenotype, but a par-
tial inhibition is also appreciable when amiodarone is added
during very early steps of infection, suggesting that the anti-
EBOV properties might derive on one side from cell structural
modifications associated with amiodarone accumulation, and
on the other side from a direct effect of the drug on specific
steps of the viral life cycle. In this respect, amiodarone could act
bymodifying lipid fluidity (Chatelain, Laruel andGillard 1985), by
increasing membrane-proximal pH (Mitterreiter et al. 2010), by
competing for negatively charged groups on the surface or by af-
fecting calcium channels, required for the maturation of the en-
dosomes and/or viral entry (Kolter and Sandhoff 2010; Gehring
et al. 2014). Interestingly, we found that amiodarone affects viral
fusion, as it has been previously reported for the U18666A in-
hibitor (Carette et al. 2011). After viral internalization, GP cleav-
age proceeds through a 50 and a 20 kDa intermediate, ultimately
generating the key 19 kDa core protein (Chandran et al. 2005;
Schornberg et al. 2006; Dube et al. 2009; Hood et al. 2010; Miller
et al. 2012). Interestingly, the artificial activation of GP by ther-
molysin treatment of viral particles before infection rescued the
effect of amiodarone. It has been demonstrated that amiodarone
can affect the stability of specific proteins, such as SP-A (Bari-
tussio et al. 2001). Here we demonstrated that the cellular con-
tent of cathepsin B and L, required for the formation of the fuso-
genic form of GP, was not affected by drug treatment. However,
we cannot exclude that amiodarone might influence the activ-
ity of these proteases, as it has been demonstrated for different
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proteolytic enzymes (Mitterreiter et al. 2010; Piccoli et al. 2011).
Furthermore, specific effects on steps subsequent to the EBOV
entry/fusion, as demonstrated in the case of the SARS coron-
avirus and HCV (Stadler et al. 2008; Cheng et al. 2013), cannot be
ruled out.
Importantly, we found that there is an additive effect be-
tween amiodarone and its pharmacologically active metabolite
MDEA on GP-mediated entry into target cells. Furthermore, our
results show that, at concentrations of clinical interest, amio-
darone and amiodarone/MDEA combination are more effective
than dronedarone and U18666A in reducing SUDV infection.
Finally, we found that the presence of a tertiary amine in
the compound plays a key role in the antiviral effect, as demon-
strated by the use here of different amiodarone derivatives and
by the anti-filovirus activity of additional amphiphilic cations
(Johansen et al. 2013; Shoemaker et al. 2013). Moreover, a hy-
drophobic moiety is also critical, perhaps regulating the interac-
tions with membranes. Overall, these observations support the
idea that the antiviral activity of amiodarone relies on its ability
to interact with membranes, to accumulate into the acidic or-
ganelles (Logan et al. 2014) and to induce an NPC-like phenotype
(Piccoli et al. 2011; Shoemaker et al. 2013; Gehring et al. 2014).
In conclusion, here we demonstrate that the anti-arrhythmic
drug amiodarone specifically interferes with the early steps of
EBOV life cycle, thus blocking viral replication. Overall, our data
provide evidence that amiodarone deserves serious considera-
tion for the treatment of EVD.
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